Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.075% vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dextrose is a monosaccharide that provides a source of calories and may restore blood glucose levels. Sodium chloride and potassium chloride are electrolytes that maintain fluid and electrolyte balance.
Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.
FDA: Fluid and electrolyte replenishment, caloric supply in parenteral nutrition,Off-label: Prevention and treatment of dehydration, maintenance of fluid and electrolyte balance
Treatment of acute bronchospasm in asthma and COPD,Reversal of dipyridamole-induced adverse effects during stress testing,Apnea of prematurity (off-label),Status asthmaticus (off-label)
Intravenous infusion. Typical adult dose is 500-1000 m L as a continuous infusion at a rate dependent on fluid and electrolyte needs, usually 80-200 m L/hour.
Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.
Dextrose: minutes (rapid cellular uptake). Sodium and chloride: half-life not applicable (regulated by renal function). Potassium: ~2-3 hours in normal renal function, prolonged in renal impairment. Clinical context: half-life of components reflects their distribution and elimination kinetics; potassium's half-life is most clinically relevant.
Terminal elimination half-life is 6-12 hours in adults, 1-5 hours in children (due to faster clearance), 20-30 hours in premature neonates, and 10-15 hours in patients with hepatic cirrhosis or heart failure. Clinical context: dosing interval adjustment required based on half-life; prolonged half-life in hepatic impairment or cardiac decompensation increases risk of toxicity.
Dextrose is metabolized via glycolysis and the Krebs cycle. Electrolytes are not metabolized but are excreted or reabsorbed by the kidneys.
Hepatic via cytochrome P450 enzymes (CYP1A2, CYP3A4, CYP2E1); saturable kinetics; extensive first-pass metabolism.
Dextrose is metabolized to CO2 and water; excretion is primarily renal (as water and electrolytes). Sodium and chloride are excreted renally (95%), with minimal fecal (<5%). Potassium is excreted renally (90%) and fecally (10%). The combination is fully eliminated via renal excretion of ions and water.
Renal excretion of unchanged theophylline (10-20%) and metabolites (80-90%). In neonates, renal excretion of unchanged drug is higher (up to 50%). Biliary/fecal excretion is negligible.
Dextrose: negligible (<1%). Sodium, chloride: not protein-bound. Potassium: negligible (<1%)
Approximately 40% bound to plasma proteins, mainly albumin. In neonates, preterm infants, and patients with hepatic cirrhosis, protein binding is reduced (free fraction increases). Binding is also saturable at high theophylline concentrations.
Dextrose: ~0.2 L/kg (related to extracellular fluid). Sodium and chloride: ~0.2 L/kg (extracellular). Potassium: ~0.4 L/kg (total body water, 98% intracellular). Clinical meaning: reflects distribution primarily into extracellular fluid for sodium/chloride/glucose; potassium distributes into total body water with high intracellular uptake.
Volume of distribution is approximately 0.45 L/kg (range 0.3-0.7 L/kg) in adults. In neonates, Vd is larger (~0.6-0.8 L/kg). Clinical meaning: Vd indicates extensive distribution into body water; loading doses are calculated using Vd (e.g., 1 mg/kg raises serum concentration by ~2 mcg/m L).
Intravenous: 100% (only route). Oral: not administered orally; enteral absorption of components would be complete but route not used for this combination.
Oral immediate-release: 100% (well absorbed). Rectal: 80-100% (absorption may be erratic). IV: 100%. No significant first-pass metabolism.
Dose adjustments are primarily based on fluid and electrolyte status. In severe renal impairment (e GFR <30 m L/min/1.73 m²), use with caution due to risk of potassium accumulation; monitor serum potassium and consider reducing infusion rate or volume.
No specific dose adjustment required for GFR >10 m L/min. For GFR <10 m L/min, reduce infusion rate by 50%.
No specific adjustments required for Child-Pugh class A, B, or C; however, monitor electrolytes in severe hepatic impairment due to risk of fluid and electrolyte imbalance.
Child-Pugh Class A: reduce dose by 25%; Class B: reduce dose by 50%; Class C: reduce dose by 75%.
Weight-based dosing: 5-10 m L/kg/dose as a continuous infusion or as needed for maintenance, with rate adjusted to avoid fluid overload. Maximum infusion rate: 5-10 m L/kg/hour depending on age and clinical status.
Loading dose: 5-6 mg/kg IV over 20-30 minutes; continuous infusion: 0.5-0.7 mg/kg/hour (age-dependent, with lower doses for younger children).
Use with caution due to decreased renal function and higher risk of fluid overload. Start at lower infusion rates (e.g., 50-100 m L/hour) and monitor serum electrolytes, renal function, and fluid status closely.
Elderly patients may have reduced clearance; consider starting at the lower end of dosing range (e.g., 0.3-0.5 mg/kg/hour) and titrate based on serum levels.
Not for use in patients with anuria, hyperkalemia, hypernatremia, or conditions where administration of these electrolytes is contraindicated. Do not administer unless solution is clear and container is undamaged.
Theophylline toxicity is dose-related and can be fatal; monitor serum theophylline levels closely; use with caution in patients with risk factors for reduced clearance (e.g., hepatic impairment, heart failure, elderly).
Risk of hyperglycemia and hyperosmolality in patients with glucose intolerance,Risk of fluid and/or solute overload with pulmonary edema or congestive heart failure,Monitor serum electrolytes, blood glucose, and fluid balance,Use with caution in patients with renal impairment, cardiac disease, or hyperkalemia
Narrow therapeutic index; severe toxicity can occur at levels >20 mcg/m L,Seizures and arrhythmias may occur without preceding symptoms,Variable clearance due to drug interactions, disease states, age, and smoking,Use with caution in peptic ulcer disease, seizure disorders, hyperthyroidism, and cardiac disease
Hyperkalemia,Hypernatremia,Anuria,Severe renal impairment,Acute myocardial infarction or pulmonary edema,Allergy to any component
Hypersensitivity to aminophylline or any component,Hypersensitivity to theophylline or ethylenediamine,Cardiac arrhythmias requiring immediate therapy (relative)
Avoid high-potassium foods such as bananas, oranges, tomatoes, potatoes, and spinach during treatment to prevent hyperkalemia. Monitor dietary sodium intake. Dextrose may increase blood glucose; diabetic patients should follow their usual carbohydrate control measures.
Avoid high-dose caffeine (coffee, tea, energy drinks, chocolate) as it may increase risk of side effects like nausea, anxiety, and tachycardia. Charcoal-broiled foods and a high-protein diet may increase theophylline clearance. Consistent dietary intake is recommended.
Dextrose, sodium chloride, and potassium chloride are physiological components; no teratogenic risk has been associated with their use at standard replacement doses. No fetal harm is expected during any trimester when used as clinically indicated.
First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high maternal doses; may cause transient neonatal tachycardia with chronic use. No documented teratogenicity.
Dextrose, sodium chloride, and potassium chloride are endogenous substances normally present in breast milk. Administration of this solution does not significantly alter milk composition; M/P ratio not applicable. Considered compatible with breastfeeding.
Aminophylline/theophylline is excreted into breast milk with an M/P ratio of approximately 0.6-0.7. Infant exposure is low (about 1-10% of maternal dose). Irritability and insomnia reported rarely. Use with caution, monitor infant for signs of theophylline toxicity.
Pregnancy may increase fluid requirements and alter electrolyte needs. Dose adjustments may be necessary based on maternal weight, gestational age, and clinical status (e.g., hyperemesis, preeclampsia). Monitor serum electrolytes and glucose to guide dosing.
Pregnancy decreases theophylline clearance by approximately 20-30% during third trimester. Dosing adjustments may be required: monitor serum levels and adjust dose to maintain therapeutic levels. Postpartum clearance returns rapidly, requiring downward dose adjustment.
Use with caution in patients with renal impairment due to potassium accumulation. Monitor serum potassium and glucose levels during prolonged administration. Avoid in patients with hyperkalemia, hypernatremia, or fluid overload. Do not administer simultaneously with blood products due to risk of hemolysis. Check for compatibility with concomitant IV medications; potassium may cause precipitation with certain drugs.
Aminophylline is a bronchodilator that releases theophylline. Monitor serum theophylline levels (therapeutic range 5-15 mcg/m L). Avoid in patients with active peptic ulcer disease, seizure disorders, or hypersensitivity to xanthines. Caution in hepatic impairment, heart failure, and elderly due to reduced clearance. Drug interactions with cimetidine, ciprofloxacin, and macrolides increase theophylline levels.
This solution is used to replace fluids and electrolytes. It contains dextrose (sugar), sodium, and potassium.,Tell your healthcare provider if you have kidney disease, heart problems, high blood pressure, diabetes, or if you are on a low-potassium diet.,Report any signs of too much potassium: muscle weakness, irregular heartbeat, tingling in hands/feet.,Report signs of high blood sugar: increased thirst, frequent urination, fruity breath.,Do not consume additional potassium-rich foods (bananas, oranges) without consulting your doctor.,You may experience pain or swelling at the IV site; notify your nurse if this occurs.,Do not stop the infusion abruptly; it is regulated by your healthcare team.
Do not exceed prescribed dose. Take exactly as directed.,Avoid caffeine-containing products (coffee, tea, cola, chocolate) as they may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, palpitations, or seizures.,Do not crush or chew extended-release forms; take with food if gastric upset occurs.,Do not stop abruptly without consulting your healthcare provider.
"Atracurium besylate, a nondepolarizing neuromuscular blocking agent, may enhance the ulcerogenic potential of oral potassium chloride by reducing gastrointestinal motility and increasing local contact time of the potassium chloride tablet with the gastric and intestinal mucosa. This prolonged exposure can heighten the risk of gastrointestinal erosion, bleeding, or perforation, particularly in patients with pre-existing lesions or receiving high-dose potassium supplementation. Clinically, this interaction necessitates close monitoring for signs of gastrointestinal injury when these agents are coadministered."
"Methscopolamine bromide, an anticholinergic agent, reduces gastrointestinal motility and delays gastric emptying, which can prolong the contact time of orally administered Potassium chloride (KCl) tablets or capsules with the gastric mucosa. This increased exposure to high concentrations of potassium in the gastrointestinal tract potentiates the local ulcerogenic effect of KCl, leading to a higher risk of esophageal, gastric, or intestinal erosions, ulcers, hemorrhage, perforation, or stricture formation. Clinically, this interaction may present with dysphagia, epigastric pain, hematemesis, melena, or signs of acute abdomen."
"Fesoterodine, an anticholinergic agent used for overactive bladder, can reduce gastric motility and prolong gastrointestinal transit time. This effect may increase the local contact time of potassium chloride tablets with the gastrointestinal mucosa, potentiating the ulcerogenic risk of potassium chloride, which can cause esophageal or intestinal ulceration, stenosis, or perforation. The interaction is clinically significant in patients with pre-existing gastrointestinal motility disorders or those taking high-dose potassium supplements."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.075% vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%, answered by our medical review team.
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.075% is a Electrolyte that works by Dextrose is a monosaccharide that provides a source of calories and may restore blood glucose levels. Sodium chloride and potassium chloride are electrolytes that maintain fluid and electrolyte balance.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.075% and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.075% is: Intravenous infusion. Typical adult dose is 500-1000 m L as a continuous infusion at a rate dependent on fluid and electrolyte needs, usually 80-200 m L/hour.. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is: Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.075% and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.075% is classified as Category A/B. Dextrose, sodium chloride, and potassium chloride are physiological components; no teratogenic risk has been associated with their use at standard replacement doses. No fetal harm . AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is classified as Category A/B. First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.